S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Tilray Stock Competitors

-0.01 (-0.15%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
18.06 million shs
Average Volume
32.98 million shs
Market Capitalization
$3.16 billion
P/E Ratio
Dividend Yield


Should you be buying Tilray stock or one of its competitors? The main competitors of Tilray include Canopy Growth (CGC), USANA Health Sciences (USNA), Cronos Group (CRON), Aurora Cannabis (ACB), Sundial Growers (SNDL), ChromaDex (CDXC), HEXO (HEXO), IM Cannabis (IMCC), Natural Alternatives International (NAII), and MediWound (MDWD). These companies are all part of the "medicinals & botanicals" industry.

Tilray vs.

USANA Health Sciences (NYSE:USNA) and Tilray (NASDAQ:TLRY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk.

Tilray received 72 more outperform votes than USANA Health Sciences when rated by MarketBeat users. Likewise, 61.47% of users gave Tilray an outperform vote while only 61.06% of users gave USANA Health Sciences an outperform vote.

USANA Health SciencesOutperform Votes
Underperform Votes
TilrayOutperform Votes
Underperform Votes

USANA Health Sciences has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Tilray has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500.

In the previous week, Tilray had 27 more articles in the media than USANA Health Sciences. MarketBeat recorded 30 mentions for Tilray and 3 mentions for USANA Health Sciences. USANA Health Sciences' average media sentiment score of 0.84 beat Tilray's score of 0.33 indicating that USANA Health Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
USANA Health Sciences
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
4 Very Positive mention(s)
8 Positive mention(s)
4 Neutral mention(s)
8 Negative mention(s)
1 Very Negative mention(s)

54.8% of USANA Health Sciences shares are held by institutional investors. Comparatively, 12.1% of Tilray shares are held by institutional investors. 0.2% of USANA Health Sciences shares are held by insiders. Comparatively, 3.2% of Tilray shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

USANA Health Sciences has higher revenue and earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.13 billion1.74$124.66 million$6.5515.46
Tilray$513.09 million6.16-$367.42 million-$1.91-3.59

USANA Health Sciences has a net margin of 11.05% compared to Tilray's net margin of -66.64%. USANA Health Sciences' return on equity of 32.68% beat Tilray's return on equity.

Company Net Margins Return on Equity Return on Assets
USANA Health Sciences 11.05% 32.68% 22.67%
Tilray -66.64% -2.57% -1.88%

USANA Health Sciences presently has a consensus target price of $124.00, indicating a potential upside of 22.47%. Tilray has a consensus target price of $12.54, indicating a potential upside of 82.80%. Given Tilray's higher possible upside, analysts clearly believe Tilray is more favorable than USANA Health Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
USANA Health Sciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1 Sell rating(s)
9 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)


USANA Health Sciences beats Tilray on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Tilray (NASDAQ:TLRY) vs. Its Competitors

TypeTilrayMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$3.16B$1.61B$4.68B$7.47B
Dividend YieldN/A2.11%1.99%2.83%
P/E Ratio-3.594.7316.9019.43
Price / Sales6.1625.436,111.82250.83
Price / CashN/A11.0862.83132.78
Price / Book0.724.218.079.66
Net Income-$367.42M-$80.34M$97.42M$155.98M
7 Day Performance-5.90%4.35%1.53%-0.68%
1 Month Performance-14.04%1.88%111.96%-3.07%
1 Year Performance-65.18%-28.82%130.87%-3.38%

Tilray Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Canopy Growth
1.1749 of 5 stars
-74.8%$3.31B$414.03M-3.163,259Positive News
USANA Health Sciences
2.1598 of 5 stars
Cronos Group
1.6565 of 5 stars
-64.0%$1.47B$46.72M-9.59665Positive News
Aurora Cannabis
1.6198 of 5 stars
Sundial Growers
1.6864 of 5 stars
-21.0%$936.37M$45.48M-3.13394Short Interest ↓
1.8448 of 5 stars
1.5532 of 5 stars
-91.3%$195.62M$97M-0.611,277Gap Down
IM Cannabis
1.825 of 5 stars
N/A$194.32M$11.86M-3.752,020Short Interest ↓
Positive News
Natural Alternatives International
1.2165 of 5 stars
N/A+5.2%$85.04M$178.52M7.22240Short Interest ↑
News Coverage
1.7581 of 5 stars
1.7964 of 5 stars
N/A+110.3%$73.04M$151.41M9.97226Short Interest ↓
News Coverage
0 of 5 stars
N/AN/A$66.78M$24.09M0.0090Short Interest ↑
Bon Natural Life
0 of 5 stars
N/AN/A$26M$18.22M0.008,787News Coverage
Gap Up
Happiness Biotech Group
1.3265 of 5 stars
N/A-72.9%$17.52M$71.49M0.00151Short Interest ↓
Gap Down
This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.